Skip to main content
. Author manuscript; available in PMC: 2013 May 16.
Published in final edited form as: Cell. 2013 Mar 28;153(1):71–85. doi: 10.1016/j.cell.2013.02.036

Figure 2. mSWI/SNF (BAF) complexes are disrupted in synovial sarcoma cells bearing the SS18-SSX1 fusion protein.

Figure 2

(A) Diagram of SS18-SSX fusion protein resulting from t(x;18) translocation, hallmark to synovial sarcoma.

(B) Anti-Brg IP (left) and total protein (right), in 293T cells as compared to synovial sarcoma (SS) cell lines, Aska-SS and Yamato-SS. See also Figure S2A-C.

(C) Glycerol gradient (10-30%, fractions 1-20) analysis on Aska-SS cell NE. See also Figure S2D,E.

(D) Side-by-side comparison of fractions 3,4 and 15,16 of Aska-SS glycerol gradient analysis.

(E) Immunodepletion studies performed on 293T and Aska-SS cells using anti-BAF155 and anti-SSX1 antibodies. (undepleted= antibody not added)